{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122316","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.798855+00:00","generated_at":"2026-05-30T04:32:43.150181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Trevi Therapeutics reports Q3 net loss of $13.2M; completes Phase 2a RIVER enrollment","bullets":["Net loss of $13.2M for Q3 2024 vs $7.7M loss in Q3 2023; R&D expenses rose to $11.2M from $6.3M.","Cash, cash equivalents and marketable securities of $65.5M at quarter end; expected runway into H2 2026.","Completed enrollment in Phase 2a RIVER trial for refractory chronic cough; topline results expected Q1 2025.","Enrolled 50% of planned 160 patients in Phase 2b CORAL trial for chronic cough in IPF; SSRE outcome expected Dec 2024; topline H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122316","json":"https://secwatch.observer/filing/0000950170-24-122316.json","markdown":"https://secwatch.observer/filing/0000950170-24-122316.md","text":"https://secwatch.observer/filing/0000950170-24-122316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024122316/0000950170-24-122316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024122316/trvi-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:32:43.150181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}